Update: How to Tell When A Drug Company Fibs About Clinical Trial Results
Osiris had no such trouble describing the study's endpoints on March 2, 2011 in a press release announcing the completion of patient enrollment:
Efficacy endpoints determined from cardiac MRI include end systolic volume, LVEF and the ability of Prochymal to preserve functional heart tissue and limit scar formation following a heart attack. In addition, functional and quality of life assessments will be performed.
Osiris did not respond to an email request for the missing data from the heart attack study. The company also chose not to hold a conference call with investors following the release of the results Monday.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.
>To submit a news tip, send an email to: tips@thestreet.com.